Previous 10 | Next 10 |
2023-12-15 14:30:49 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips As technology advances in our era, biotechnology is not far behind. Modern day medical advancements are impressive, and the company’s making these strides have incredible results to show...
2023-12-13 15:53:47 ET More on Neurocrine Biosciences Neurocrine Biosciences: Fear Not The IRA Neurocrine Biosciences, Inc. (NBIX) Q3 2023 Earnings Call Transcript Neurocrine Biosciences, Inc. 2023 Q3 - Results - Earnings Call Presentation Neurocrine gets FDA...
2023-12-05 17:16:18 ET More on Neurocrine Biosciences Neurocrine Biosciences: Fear Not The IRA Neurocrine Biosciences, Inc. (NBIX) Q3 2023 Earnings Call Transcript Neurocrine Biosciences, Inc. 2023 Q3 - Results - Earnings Call Presentation Neurocrine settles ...
Neurocrine Biosciences Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Crinecerfont in Congenital Adrenal Hyperplasia PR Newswire Company Today Also Provided Updates on R&D Portfolio and Strategy at Investor Event Crinec...
2023-12-01 10:17:15 ET The UBS pharma equity team is out with a quant list of most crowded stocks on the long and short side. Crowding is a sentiment metric that basically measure popularity in positioning (long or short). It indicates if a stock has a significantly above-average number...
Neurocrine Biosciences to Host Analyst Day on December 5, 2023 PR Newswire SAN DIEGO , Dec. 1, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), a leading neuroscience-focused biopharmaceutical company, will hold its Analyst Day focused on its R&a...
2023-11-30 12:16:34 ET Summary Neurocrine Biosciences' stock has been stagnant due to a lack of appreciation for positive updates and the modest mid-stage pipeline setbacks. The company recently settled with generic filers, ensuring no generic launch of Ingrezza until 2038 and hig...
2023-11-30 09:53:30 ET More on Neurocrine Biosciences Neurocrine's Crinecerfont Delivered, But The Street Has Been Slow To Reward The Success Neurocrine settles all patent disputes related to movement disorder therapy Neurocrine reports Phase 2 study failures for two...
2023-11-13 13:23:47 ET More on Neurocrine Biosciences Neurocrine Biosciences, Inc. (NBIX) Q3 2023 Earnings Call Transcript Neurocrine Biosciences, Inc. 2023 Q3 - Results - Earnings Call Presentation Neurocrine's Crinecerfont Delivered, But The Street Has Been Slow To...
Neurocrine Biosciences Announces Settlement of INGREZZA Abbreviated New Drug Application (ANDA) Litigation PR Newswire SAN DIEGO , Nov. 13, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), a leading neuroscience-focused biopharmaceutical company,...
News, Short Squeeze, Breakout and More Instantly...
Neurocrine Biosciences Inc. Company Name:
NBIX Stock Symbol:
NASDAQ Market:
Neurocrine Biosciences Inc. Website:
Neurocrine Biosciences Launches INGREZZA® SPRINKLE (valbenazine) Capsules to Ease Administration for Patients Experiencing Dysphagia or Difficulty Swallowing PR Newswire SAN DIEGO , July 18, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX...
2024-07-12 10:00:03 ET Jeffrey Hung from Morgan Stanley issued a price target of $170.00 for NBIX on 2024-07-12 08:10:00. The adjusted price target was set to $170.00. At the time of the announcement, NBIX was trading at $146.5. The overall price target consensus is at $...
Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2024 Financial Results PR Newswire Conference Call and Webcast Scheduled for Thursday, August 1 SAN DIEGO , July 11, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasd...